Last kr11.20 SEK
Change Today +0.15 / 1.36%
Volume 33.5K
BIOT On Other Exchanges
Symbol
Exchange
BIOT is not on other exchanges.
As of 11:29 AM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).

biotage ab (BIOT) Snapshot

Open
kr11.05
Previous Close
kr11.05
Day High
kr11.20
Day Low
kr11.05
52 Week High
05/2/14 - kr12.35
52 Week Low
02/4/14 - kr9.55
Market Cap
724.8M
Average Volume 10 Days
44.1K
EPS TTM
kr0.75
Shares Outstanding
64.7M
EX-Date
04/29/14
P/E TM
15.0x
Dividend
kr0.60
Dividend Yield
5.36%
Current Stock Chart for BIOTAGE AB (BIOT)

Related News

No related news articles were found.

biotage ab (BIOT) Related Businessweek News

No Related Businessweek News Found

biotage ab (BIOT) Details

Biotage AB provides solutions, knowledge, and experience in the areas of analytical chemistry, medicinal chemistry, and peptide synthesis, as well as separation and purification in the United States, Europe, and Japan. It offers systems and related consumables for evaporation, flash purification, microwave synthesis, peptide synthesis and purification, sample preparation, work-up tools, and process development solutions in organic chemistry and analytical chemistry areas. The company also offers contract-research services, as well as develops and produces polymer based materials. Biotage AB sells its products to pharmaceutical and biotech companies, contract research organizations and contract manufacturing organizations, academic institutions, and food producers. The company is headquartered in Uppsala, Sweden.

292 Employees
Last Reported Date: 08/14/14

biotage ab (BIOT) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr2.9M
Compensation as of Fiscal Year 2013.

biotage ab (BIOT) Key Developments

Biotage Announces Success in Re-examination Proceedings

U.S. Court of Appeals for the Federal Circuit have affirmed U.S Patent and Trademark Office’s Patent Trial and Appeal Board decisions to reject all claims in U.S patents 7,138,061, 7,381,327 and 7,410,571. A lawsuit was filed against Biotage by Scientific Plastic Products Inc. concerning alleged infringement of the U.S patents no 7,138,061, 7,381,327 and 7,410,571. Biotage then filed requests with the U.S Patent and Trademark Office for re-examination of all patent claims in the three patents mentioned above. At the same time Biotage moved to stay the lawsuit in the district court pending the outcome of the re-examination proceedings with the consent of SPP, and the court stayed the district court lawsuit pending resolution of the reexamination proceedings. The U.S Patent and Trademark Office’s Patent Trial and Appeal Board affirmed the Examiner’s decision to reject all claims of U.S patents 7,138,061, 7,381,327 and 7,410,571. SPP filed an appeal to the U.S. Court of Appeals for the Federal Circuit. On September 10, 2014, the appeals court affirmed the rejections of all claims.

Biotage AB Reports Unaudited Consolidated and Parent Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Biotage AB reported unaudited consolidated and parent earnings results for the second quarter and six months ended June 30, 2014. For the quarter, on consolidated basis, the company reported net sales of SEK 120.383 million compared to SEK 116.344 million a year ago. Operating profit was SEK 13.549 million compared to SEK 12.066 million a year ago. Profit before income tax was SEK 15.933 million compared to SEK 13.073 million a year ago. Total profit for the period was SEK 15.394 million or SEK 0.24 per diluted share compared to SEK 12.908 million or SEK 0.19 per diluted share a year ago. Cash flow from operating activities was SEK 24.607 million compared to SEK 7.074 million a year ago. Acquisition of intangible assets was SEK 6.258 million compared to SEK 8.141 million a year ago. Acquisition of property, plant and equipment was SEK 1.545 million compared to SEK 2.651 million a year ago. For the six months, on consolidated basis, the company reported net sales of SEK 234.100 million compared to SEK 219.578 million a year ago. Operating profit was SEK 23.013 million compared to SEK 18.143 million a year ago. Profit before income tax was SEK 25.848 million compared to SEK 16.689 million a year ago. Total profit for the period was SEK 23.460 million or SEK 0.36 per diluted share compared to SEK 15.988 million or SEK 0.23 per diluted share a year ago. Cash flow from operating activities was SEK 35.425 million compared to SEK 22.305 million a year ago. Acquisition of intangible assets was SEK 12.961 million compared to SEK 16.885 million a year ago. Acquisition of property, plant and equipment was SEK 4.777 million compared to SEK 3.895 million a year ago. For the quarter, on parent basis, the company reported net sales of SEK 0.619 million compared to SEK 0.600 million a year ago. Operating loss was SEK 4.223 million compared to SEK 4.965 million a year ago. Loss before income tax was SEK 2.464 million compared to SEK 2.739 million a year ago. Total loss for the period was SEK 2.464 million compared to SEK 2.739 million a year ago. Investments in intangible fixed assets amounted to SEK 0.2 million compared to SEK 0.2 million a year ago. For the six months, on parent basis, the company reported net sales of SEK 1.225 million compared to SEK 1.197 million a year ago. Operating loss was SEK 9.012 million compared to SEK 9.015 million a year ago. Loss before income tax was SEK 6.630 million compared to SEK 36.328 million a year ago. Total loss for the period was SEK 6.630 million compared to SEK 36.328 million a year ago. Investments in intangible fixed assets amounted to SEK 0.5 million compared to SEK 0.3 million a year ago.

Biotage AB Approves Dividend for the Year 2013

The annual general meeting of Biotage AB held on April 28, 2014, resolved a dividend of SEK 0.60 per share. Record date for dividend was resolved to be May 2, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOT:SS kr11.20 SEK +0.15

BIOT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fluidigm Corp $28.45 USD -0.16
International Stem Cell Corp $0.10 USD 0.00
Luminex Corp $19.36 USD +0.45
QIAGEN NV €18.20 EUR +0.10
Sequenom Inc $3.35 USD -0.04
View Industry Companies
 

Industry Analysis

BIOT

Industry Average

Valuation BIOT Industry Range
Price/Earnings 14.2x
Price/Sales 1.5x
Price/Book 1.5x
Price/Cash Flow 13.9x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTAGE AB, please visit www.biotage.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.